Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960348 | 0.92 | LMNA (0.36) | LMNAGAAGFERTDO2CSF1R | |
| SCHEMBL2950115 | 0.89 | LMNA (0.35) | LMNAGAAGFERKMT2AMEN1 | |
| SCHEMBL2950043 | 0.88 | MAP3K8 (0.41) | TDO2MAP3K8 | |
| SCHEMBL2952952 | 0.87 | CHRNA7 (0.35) | LMNAGAAGFERMAP3K8RAPGEF4 | |
| SCHEMBL2956230 | 0.86 | EGFR (0.37) | LMNAGAAKMT2AMEN1TDO2 | |
| SCHEMBL2958784 | 0.85 | IDO1 (0.39) | LMNAGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2959762 | 0.84 | CDK4 (0.38) | GAAALDH1A1MAPTCDK4SMN1; SMN2 | |
| SCHEMBL2954060 | 0.83 | NPC1 (0.37) | LMNAGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2956795 | 0.83 | MAP2K1 (0.34) | LMNAGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2952187 | 0.82 | POLB (0.35) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | LMNA 3193/4885GAA 4059/4885GFER 1084/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | LMNA 3052/4885GAA 4234/4885GFER 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.